Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?

abstract：:Proliferative diabetic retinopathy (PDR) demands both more effective and less expensive biologically based treatments. Our understanding of the pathophysiology of the disease is increasing as new biochemical pathways are identified. Most reports emphasize proangiogenic stimuli, with the natural inhibitory elements rec...

journal_title：Expert opinion on investigational drugs

authors： Hernández C,Simó R

更新日期：2007-08-01 00:00:00

abstract：:CGRP is a potent vasodilator that has been shown to have a physiological and/or pathological role in neurogenic inflammation, headaches including migraine, thermal injury, circulatory shock, pregnancy and menopause, hypertension and heart failure and is known to be cardioprotective. CGRP is also a positive inotrope an...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2001-06-01 00:00:00

abstract：:'Male factor' problems contribute to subfertility in a significant proportion of couples. In some instances, defective sperm production has qualitative and/or quantitative effects on the semen profile; in others, no obvious defects can be detected, yet spermatozoa are non-fertilising. Recent studies have revealed that...

journal_title：Expert opinion on investigational drugs

authors： Fraser LR

更新日期：1997-12-01 00:00:00

abstract：:Type 2 diabetes is a chronic metabolic disease that adversely affects both the quality and longevity of life. The disease is characterised by elevated blood glucose (hyperglycaemia) that is associated with microvascular complications and increased macrovascular risk. Existing oral agents, either alone or in combinatio...

journal_title：Expert opinion on investigational drugs

authors： Coghlan M,Leighton B

更新日期：2008-02-01 00:00:00

abstract：INTRODUCTION:Epidermal growth factor receptor (EGFR) targeted treatment has been evaluated but has not shown a clear clinical benefit for breast cancer. This review article aims to consider the knowledge of the biological background of EGFR pathways in dissecting clinical studies of EGFR targeted treatment in breast ca...

journal_title：Expert opinion on investigational drugs

authors： Matsuda N,Lim B,Wang X,Ueno NT

更新日期：2017-04-01 00:00:00

abstract：:COPD is a chronic disease of the lung that is characterised by decreased air flow and associated abnormal inflammatory responses of the lungs. A total of 80% of COPD incidences are observed in patients with history of smoking tobacco. The chronic condition of COPD is characterised by airway remodelling, which leads to...

journal_title：Expert opinion on investigational drugs

authors： Srivastava PK,Dastidar SG,Ray A

更新日期：2007-07-01 00:00:00

abstract：INTRODUCTION:The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) mainly comprise polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF, primary or post-PV/ET). Therapy in PV and ET focuses on minimizing thrombosis and bleeding risk, while in MF, prolongation of survival is an ...

journal_title：Expert opinion on investigational drugs

authors： Bose P,Verstovsek S

更新日期：2016-12-01 00:00:00

abstract：INTRODUCTION:Rheumatoid arthritis (RA) is a chronic inflammatory auto-immune disease that can lead to permanent disability and deformity. Despite current treatment modalities, many patients are still unable to reach remission. Interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors are novel agents designed to s...

journal_title：Expert opinion on investigational drugs

authors： Wiese MD,Manning-Bennett AT,Abuhelwa AY

更新日期：2020-05-01 00:00:00

abstract：:Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world for those patients aged 50 years or older. Neovascular AMD, a subtype characterized by the growth of new, pathologic blood vessels, results in most of the cases of severe and rapid vision loss associated with AMD. A critical ...

journal_title：Expert opinion on investigational drugs

authors： Barakat MR,Kaiser PK

更新日期：2009-05-01 00:00:00

abstract：:Therapeutic angiogenesis has yielded promising results in animal models, including the demonstration of newly created blood vessels, increased perfusion and functional benefits. On the other hand, clinical studies using similar methods of angiogenesis have so far been disappointing. The possibility that endothelial dy...

journal_title：Expert opinion on investigational drugs

authors： Kapila V,Sellke FW,Suuronen EJ,Mesana TG,Ruel M

更新日期：2005-01-01 00:00:00

abstract：INTRODUCTION:EGFR has been implicated in various malignancies such as NSCLC, breast, head and neck, and pancreatic cancer. Numerous drugs have been developed in order to target the tyrosine domain of EGFR as an approach in cancer treatment. AREAS COVERED:This article focuses on the different generations of EGFR tyrosi...

journal_title：Expert opinion on investigational drugs

authors： Lee CC,Shiao HY,Wang WC,Hsieh HP

更新日期：2014-10-01 00:00:00

abstract：:The management of acute myocardial infarction (AMI) has changed dramatically over the last two decades, with the addition of fibrinolytic agents and primary coronary intervention (PCI). The more recent development of the glycoprotein (GP) IIb/IIIa antagonists, a new class of potent antiplatelet drugs, has the potentia...

journal_title：Expert opinion on investigational drugs

authors： Ferguson JJ,Vaisman D

更新日期：2001-11-01 00:00:00

abstract：:Introduction: Cyclin-dependent kinase 7 (CDK7) is a part of the CDK-activating kinase family (CAK) which has a key role in the cell cycle and transcriptional regulation. Several lines of evidence suggest that CDK7 is a promising therapeutic target for cancer. CDK7 selective inhibitors such as SY-5609 and CT7001 are in...

journal_title：Expert opinion on investigational drugs

authors： Liang H,Du J,Elhassan RM,Hou X,Fang H

更新日期：2021-01-01 00:00:00

abstract：INTRODUCTION:Compounds that inhibit or modulate γ-secretase, the pivotal enzyme which generates β-amyloid (Aβ), are potential therapeutics for Alzheimer's disease (AD). AREAS COVERED:This article briefly reviews the profile of γ-secretase inhibitors that have reached the clinic and discusses the clinical issues surrou...

journal_title：Expert opinion on investigational drugs

authors： Imbimbo BP,Panza F,Frisardi V,Solfrizzi V,D'Onofrio G,Logroscino G,Seripa D,Pilotto A

更新日期：2011-03-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Antibacterial drug discovery and development has slowed considerably in recent years, with novel classes discovered decades ago and regulatory approvals tougher to get. Traditional approaches and the newer genomic mining approaches have not yielded novel classes of antibacterial compounds. Inste...

journal_title：Expert opinion on investigational drugs

authors： Devasahayam G,Scheld WM,Hoffman PS

更新日期：2010-02-01 00:00:00

abstract：INTRODUCTION:Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies. AREAS COVERED:We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgk...

journal_title：Expert opinion on investigational drugs

authors： Chang A,Schlafer D,Flowers CR,Allen PB

更新日期：2018-01-01 00:00:00

abstract：:Introduction: Renal cell carcinoma (RCC) consists of distinct clinical and biologic entities, with an urgent need for novel therapies targeting histology-specific molecular drivers of cancer growth. The MET pathway is now being targeted by multiple novel agents in clinical development. This review highlights the upcom...

journal_title：Expert opinion on investigational drugs

authors： Nandagopal L,Sonpavde GP,Agarwal N

更新日期：2019-10-01 00:00:00

abstract：INTRODUCTION:Sepsis with Bacillus anthracis infection has a very high mortality rate despite appropriate antibiotic and supportive therapies. Over the past 15 years, recent outbreaks in the US and in Europe, coupled with anthrax's bioterrorism weapon potential, have stimulated efforts to develop adjunctive therapies to...

journal_title：Expert opinion on investigational drugs

authors： Ohanjanian L,Remy KE,Li Y,Cui X,Eichacker PQ

更新日期：2015-01-01 00:00:00

abstract：:With the current standard chemotherapy regimens only approximately 25% of acute myelogenous leukaemia (AML) patients survive > 5 years. Aurora kinases are overexpressed in many human cancers. VX-680 inhibited Aurora-A, -B, -C and the FMS-like tyrosine kinase-3 with apparent inhibitory constants of 0.6, 18, 4.6 and 30 ...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2004-09-01 00:00:00

abstract：INTRODUCTION:Obesity is a major health threat in the Western world because of its high incidence and prevalence, and its association with metabolic and cardiovascular disease as well as cancer. The reduction of food intake in obese patients can be achieved only transiently (generally for no longer than 6 months), in th...

journal_title：Expert opinion on investigational drugs

authors： Folli F,Guardado Mendoza R

更新日期：2011-12-01 00:00:00

abstract：:The beneficial effect of beta-hydroxy-beta-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in primary prevention of coronary artery disease in those with hypercholesterolaemia and in secondary prevention in those with established coronary vascular disease are now well known. A growing body of eviden...

journal_title：Expert opinion on investigational drugs

authors： Delanty N,Vaughan CJ,Sheehy N

更新日期：2001-10-01 00:00:00

abstract：INTRODUCTION:Progesterone receptor (PR) agonists (progestins) and antagonists are developed for female contraceptives. However, non-contraceptive applications of newer progestins and PR modulators are being given more attention. AREAS COVERED:The newer PR agonists including drospirenone, nomegestrol, trimegestone, die...

journal_title：Expert opinion on investigational drugs

authors： Su Y,Lian QQ,Ge RS

更新日期：2012-01-01 00:00:00

abstract：:Asthma and chronic obstructive pulmonary disease (COPD) are diseases of the airways with an underlying inflammatory component. The prevalence and healthcare burden of asthma and COPD is still rising and is predicted to continue to rise in the current century. The beta-agonists and corticosteroids form the basis of the...

journal_title：Expert opinion on investigational drugs

authors： Hele DJ,Belvisi MG

更新日期：2003-01-01 00:00:00

abstract：:Improving the tumour selectivity of cytotoxic drugs through conjugation to tumour-reactive monoclonal antibodies may lead to novel, more potent agents for cancer therapy. The maytansinoid drugs are 100- to 1000-fold more cytotoxic in vitro than current clinical anticancer drugs. We recently demonstrated that conjugati...

journal_title：Expert opinion on investigational drugs

authors： Liu C,Chari RV

更新日期：1997-02-01 00:00:00

abstract：:Anorexia nervosa (AN), bulimia nervosa (BN) and binge eating disorder (BED) each occur in about 0.5-1.5% of the population in westernised countries, and primarily affect women. At present, a variety of pharmacological treatments are used in addition to psychotherapy, with antidepressants being most the common. Current...

journal_title：Expert opinion on investigational drugs

authors： Crow S

更新日期：1997-04-01 00:00:00

abstract：:Venous and arterial thromboembolism are a major cause for morbidity and mortality. The list of established drugs for the prevention of thrombus formation and embolisation includes heparins, hirudin and derivatives, aspirin, ADP and glycoprotein IIb/IIIa receptor antagonists, as well as vitamin K antagonists. Several l...

journal_title：Expert opinion on investigational drugs

authors： Ruef J,Katus HA

更新日期：2003-05-01 00:00:00

abstract：:The discovery of new antibacterial drugs can be based either upon empirical screening methods or structure-based design. Empirical methods utilise both intact bacteria and isolated biochemical targets for high throughput screening of natural product or chemical libraries to detect inhibitor leads. Structure-based meth...

journal_title：Expert opinion on investigational drugs

authors： Chopra I

更新日期：1997-08-01 00:00:00

abstract：:Therapeutic angiogenesis is a novel approach to the treatment of ischaemic or occlusive coronary and peripheral vascular disease. The therapeutic concept is based on the restoration of distal blood flow by the enlargement of existing vessels and tissue perfusion by the induction of new capillaries. Initial studies hav...

journal_title：Expert opinion on investigational drugs

authors： Tarzami ST,Singh JP

更新日期：2004-10-01 00:00:00

abstract：:The introduction of HIV-1 protease inhibitors in 1995 ushered in the era of highly active antiretroviral therapy. For the first time, inhibition of two key enzymes responsible for HIV replication, reverse transcriptase and protease, was possible. The combination of two nucleoside reverse transcriptase inhibitors with ...

journal_title：Expert opinion on investigational drugs

authors： Piliero PJ

更新日期：2002-09-01 00:00:00

abstract：INTRODUCTION:Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Pharmacological treatment of AD includes Anticholinesterase Inhibitors (AChEIs) for mild-moderate AD, and memantine for severe AD. These drugs provide mainly symptomatic short-term benefits without clearly influencing the progres...

journal_title：Expert opinion on investigational drugs

authors： Galimberti D,Scarpini E

更新日期：2017-01-01 00:00:00